NCT06923397Recruiting
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
This study aims to see if a 12-week exercise program designed to reduce long periods of inactivity is feasible in newly diagnosed lymphoma participants receiving R-CHOP or POLA-R-CHP chemotherapy treatments, and whether it can improve heart health and reduce chemotherapy drug side effects.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 4 Apr 2025
- Start date
- 5 Jun 2025
- Primary completion date
- 28 Nov 2026
- Lead sponsor
- Dana-Farber Cancer Institute
- Diseases
- Hodgkin lymphoma
- NCT number
- NCT06923397
What you commit to
- Study type: Interventional
- Planned participants: 24
- From 5 Jun 2025 to the primary completion date, 28 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving treatment for other active malignancies (except basal cell carcinoma). This study is exclusively targeting lymphoma chemotherapy-related effects.
- Patients currently taking weight loss drugs.
- Unable to travel to DFCI Longwood campus for necessary data collection and chemotherapy infusions.
Other
- Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities likely require supervised exercise for safety, and part of this study involves unsupervised exercise; therefore, for safety reasons, these persons are excluded.
- Participate in more than 60 minutes of structured moderate-to-vigorous exercise per week over the last month. Excess additional exercise is a confounding factor in assessing the effect of the current interrupted sedentary time intervention.
- Subjects who in the opinion of the investigators may not be able to comply with the safety monitoring requirements of the study.
Who the study is looking for
- Ability to understand and the willingness to sign informed consent prior to any study- related procedures.
- Patients diagnosed with lymphoma.
- Will receive first line R-CHOP or POLA-R-CHP chemotherapy regimens, patients do not need to be within a certain timeframe from diagnosis.
- Aged ≥18 years; due to the rarity of the disease in those \<18 years, this age bracket will not be included.
- Engaging in ≤60-minutes of structured moderate or vigorous intensity exercise.
- Have physician clearance to participate in exercise.
- Speak English.
- Willing to travel to Dana-Farber Cancer Institute for necessary data collection and exercise sessions.
- Access to a phone that can receive text messages.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.